Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. - Wikidata - wikimedia - TriplyDB

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

http://www.wikidata.org/entity/Q34504188

about

Process of Fragment-Based Lead Discovery-A Perspective from NMR Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway The clinical implications of gene mutations in chronic lymphocytic leukaemia Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor Mitochondrial apoptosis and BH3 mimetics The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia Second-generation inhibitors of Bruton tyrosine kinase In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci Management of elderly and unfit patients with chronic lymphocytic leukemia.The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Richter transformation of CLL.Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.Loss of PUMA (BBC3) does not prevent thrombocytopenia caused by the loss of BCL-XL (BCL2L1).Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints.Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma.Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China.Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia.Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1 Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine.Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors.Potential mechanisms of resistance to venetoclax and strategies to circumvent it.Distinctive Expression of Bcl-2 Factors in Regulatory T Cells Determines a Pharmacological Target to Induce Immunological Tolerance Bcl-2 is a critical mediator of intestinal transformation Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions.The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.Chronic lymphocytic leukemia therapy: new targeted therapies on the way Alectinib, Ceritinib, Elotuzumab, and Venetoclax.A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells Synergistic anti-leukemic interactions between ABT-199 and panobinostat in acute myeloid leukemia ex vivo Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia.Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation.How to unleash mitochondrial apoptotic blockades to kill cancers?New Pharmacotherapies in Chronic Lymphocytic Leukemia.

P2860

Q26738768-6D8180B9-929D-4C2A-8B99-357E914C08D0 Q26746697-308F0A1A-E48B-414A-8CE5-774D4E1C0F50 Q26749214-F1E28DBF-5D8E-48DE-B7EF-9275198A55FE Q28066316-7A037E13-B69E-4CE7-A50A-5AF10B5B01FD Q28069552-0D8FFFC2-4CEA-45D6-9ADC-3CE4FBA15691 Q28075504-E0E0AA0F-F932-401F-8201-11460C22822B Q28075683-0ADB0E71-2EDB-44BD-A9B7-5F410E7EB2BF Q28076118-2E41CF79-4471-4ABC-8367-BA10E0F096BB Q28554677-5A4CB248-0A0F-42B8-A0E9-B812C51B6121 Q29248527-81506BD7-52CD-435E-83B2-AB9D7332EF71 Q30243914-E58D74E2-E819-4B8B-ACC6-57134001CEE6 Q30243968-73448D5E-8C44-43C7-86EC-E34F93485960 Q30249283-C0760424-3112-4D50-87D0-E665C27C342D Q31097476-C99D02E2-E31F-41E8-9DC6-6F240647FDD5 Q33432478-9B731038-55AA-4FC9-B1DF-7C81AF7887D4 Q33433407-2AC0E5A3-51FE-402B-BF59-CBCE930377DF Q33436535-8AA71A3E-4FE5-4758-B36C-13F3A4B990B7 Q33438428-A1E6BD79-987A-4549-B641-217EE5BE36A9 Q33438494-F9929164-2863-42CB-953A-9F82D6040A64 Q33649977-D39E490F-654F-474E-AF09-A74F9544D3A8 Q33702409-7EC8A48F-059D-4E63-A415-1131CF2841B4 Q33779035-5759310F-3031-48EA-A534-33575EA201F2 Q33823065-86D1770A-D584-4EC5-8B95-8447470D3BF3 Q36280596-089A07B1-01D8-4381-BA63-DEDE03A230F4 Q36392035-C28FA20C-9FDC-4249-B591-ADB18F7439AA Q36632500-D4711E10-7DE7-4A38-A258-9CDD4445A2AA Q36675203-0517A0FF-A0BB-47B0-B8C6-37ADF48A6FB5 Q36735325-F393F4F6-2AEC-4701-9BA7-487E6C0DAD7F Q37035832-7AE17E67-62A3-4AF9-BD69-2F48D2B12DB4 Q37113544-9FE78570-9ACC-4EF1-B94C-48588CE1D823 Q37167686-3721A616-AB84-4B01-B3CF-1E17A748C72B Q37168430-23352143-FFA4-4A2D-95A8-C93D704759E2 Q37209768-51EFD5BF-AC19-4C74-8B12-5B850D8F432F Q37293167-3F167A62-ECA1-4DF5-93B8-376F66ED827E Q37330840-07DB9738-C552-479F-B63F-9B9208B60B4A Q37376388-31BBEFAE-5C40-4256-81DE-E31BD53068E2 Q37429218-EF016932-BBF5-4571-B6C7-D68D28746EBB Q37521403-4D4FF26F-9C53-4B4F-BF87-8BDA51AE697F Q37587294-D4AFF339-BC0F-48F8-807C-E70350B4230B Q37605306-DE6D3A2B-EF86-43BB-B56B-38F8BF50CCB1

P2860

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

http://www.wikidata.org/entity/Q34504188

description

2015 nî lūn-bûn

@nan

2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

@ast

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

@en

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

@nl

type

label

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

@ast

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

@en

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

@nl

prefLabel

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

@ast

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

@en

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

@nl

P1433

Q34504188-F4F87701-F84C-4233-B608-C94B45076868

P1476

Q34504188-5D21A123-0C0B-4470-910D-1DD346FAEA40

P2093

Q34504188-19CA2004-69E5-4460-B55E-C2F4B50BE274

Q34504188-19FA827F-93CC-423E-ACE6-B1CF83043516

Q34504188-1B7FB623-D006-43E7-8083-A87332EC380B

Q34504188-21E6BF49-4BA9-46C7-97E4-C0B0ED3DAC31

Q34504188-2FFF8338-4C2C-4DA0-A2E7-D90B76DD721E

Q34504188-32B4D885-BAB3-40FB-AD7B-E090B5D3FAE0

Q34504188-3F66130E-3261-4871-B3C1-F3B14E336DDE

Q34504188-4361FDD2-C37A-4711-A4C5-6FC93CA88B52

Q34504188-59833BFC-9B54-48FE-B771-E8B84E3D528C

Q34504188-7B04D212-4C69-419D-8B97-FF420C55512A

P304

Q34504188-39EC2CF7-7C5F-4D05-9205-972D4174226C

P31

Q34504188-23983AD2-74CA-4375-86AA-0B7378922F77

P356

Q34504188-02D0A3B1-1BE4-46F5-99F8-E0191168EAF4

P407

Q34504188-8760321D-A9E8-4B34-8D69-B62784A2F241

P433

Q34504188-37F8ACDA-3A2E-4661-A23C-FE5D8E14BF7F

P478

Q34504188-BBB07AD0-485A-40BB-957B-29897376EE4A

P50

Q34504188-099AC0CE-6FFD-4AF4-BECA-7A67BE2FF9AF

Q34504188-4AA9CA24-B0D7-4473-92E0-A5962AD4D4F2

P577

Q34504188-ACD48F24-A9C5-4E38-A190-14924440EE09

P698

Q34504188-45D9299C-5CAF-4ACB-BD3C-43614ADB819C

P921

Q34504188-3F8E1C99-CB50-47D2-BE0B-6EF48B77469F

Q34504188-9DF72A50-CCE1-49E7-A539-1C737F99E356

P356

P1433

The New England Journal of Medicine

P1476

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

@en

P2093

Brad S Kahl

http://www.w3.org/2001/XMLSchema#string

Elisa Cerri

http://www.w3.org/2001/XMLSchema#string

Jennifer R Brown

http://www.w3.org/2001/XMLSchema#string

John F Gerecitano

http://www.w3.org/2001/XMLSchema#string

John F Seymour

http://www.w3.org/2001/XMLSchema#string

John M Pagel

http://www.w3.org/2001/XMLSchema#string

Lori Gressick

http://www.w3.org/2001/XMLSchema#string

Martin Dunbar

http://www.w3.org/2001/XMLSchema#string

Mary Ann Anderson

http://www.w3.org/2001/XMLSchema#string

Matthew S Davids

http://www.w3.org/2001/XMLSchema#string

P304

311-322

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1513257

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

374

http://www.w3.org/2001/XMLSchema#string

P50

Andrew W Roberts

William G Wierda

P577

2015-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26639348

http://www.w3.org/2001/XMLSchema#string

P921